Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...
A new experimental scalp treatment called clascoterone has shown strong results in helping reduce male-pattern hair loss (also known as androgenetic alopecia, or AGA). Experts call the results ...
Topline results from the phase 3 EVOKE and EVOKE+ studies of oral semaglutide in early Alzheimer’s disease (AD) show that the trials did not meet their primary endpoints, Novo Nordisk announced. The ...
- PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage ...
Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...
Doron Therapeutics, a clinical-stage biotechnology company developing novel biologics for musculoskeletal diseases, today announced that the initial patients have been dosed in its Phase 3 clinical ...
An addiction treatment chain that operates primarily in western and midwestern states plans to open a treatment center at the Ephrata Borough property formerly owned by the defunct Retreat Behavioral ...
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
Esketamine monotherapy was associated with significantly alleviated symptoms of treatment-resistant depression (TRD) at day 28 compared to placebo in a new phase 4 trial. The research extends findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results